Ligelizumab treatment for severe asthma: learnings from the clinical development programme

OBJECTIVE: Ligelizumab is a humanised IgG1 anti‐IgE antibody that binds IgE with higher affinity than omalizumab. Ligelizumab had greater efficacy than omalizumab on inhaled and skin allergen provocation responses in mild allergic asthma. This multi‐centre, randomised, double‐blind study was designe...

Descripción completa

Detalles Bibliográficos
Autores principales: Trischler, Jordis, Bottoli, Ivan, Janocha, Reinhold, Heusser, Christoph, Jaumont, Xavier, Lowe, Phil, Gautier, Aurelie, Pethe, Abhijit, Woessner, Ralph, Zerwes, Hans‐Günter, Zielen, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958305/
https://www.ncbi.nlm.nih.gov/pubmed/33747510
http://dx.doi.org/10.1002/cti2.1255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958305/
https://www.ncbi.nlm.nih.gov/pubmed/33747510
http://dx.doi.org/10.1002/cti2.1255

Ejemplares similares